Check out this article from The New York Times. Because I'm a subscriber, you can read it through this gift link without a subscription.
Alzheimer’s Drug Slows Cognitive Decline in Key Study Biogen and Eisai reported the finding from a large late-stage clinical trial of lecanemab, a drug they are developing. https://www.nytimes.com/2022/09/27/business/alzheimers-drug-biogen-lecanemab.html?unlocked_article_code=rsZSU2JmKGGy-_Exjmzb0hw2EMcmJiJYnwt1zMbDTejar-vnrnx0fQcD2v-PMNM_UJcVnoAflP6dsRoEug0g5r9dtMCLUxH9-ds6NjY0w-GEKrFHIIjqJ14Iaey6_w0tFTT4TN7kPOskkIHKeVA63t-ksQLAuUAVKhi6_n2EXmucOinMb-tT5kfVPQyw5a7Mal4GtemM_52b1wWOXEAWXU6TM356bxYRlZfEHoz76nmCZI7PijXZSJUsw8oqOi7DhWw_ieq64o02NJrv94QCFsX9_A6v771VDrcnedpoRUmV_ZDQVeSm_bjBTRsgdL2bPwsEhpVDpuJ6AFGhXPlkgizMunPd8OMUrylq&smid=em-share -- You received this message because you are subscribed to the Google Groups "Everything List" group. To unsubscribe from this group and stop receiving emails from it, send an email to everything-list+unsubscr...@googlegroups.com. To view this discussion on the web visit https://groups.google.com/d/msgid/everything-list/CAJPayv1%3Doy9S18afUSgmtp9XtpGEvF%3D1AP%2B4i6VdATWRR6B7Sw%40mail.gmail.com.
